Phacilitate Leaders Forum

11-12 SEPTEMBER 2018

Register your interest for 2019
 

Phacilitate Leaders Europe Agenda 2018

Loading

Panel – Re-evaluating our strategies for combination partnering

11-Sep-2018
Immuno-Oncology Frontiers Europe
  • How does BMS’s selection of a single preferential partner impact biotech and big pharma?
     
  •  What are the most effective partnering models in their eyes for combination development?
     
  • If you are a biotech – should you seek to partner right up front? Or try to go it alone?
Chairperson
Victoria English, Editor - MedNous
Speakers
Bernd Muehlenweg, CBO - Nanobiotix
Mark Throsby, CSO - Merus N.V.
Ro Wickramsinghe , Directory of Oncology Evaluation - AstraZeneca
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd

 

Search